Ogloblina O, Beckert R, Belova L, Bauer M, Smirnov M
National Cardiology Research Center of Russia Academy of Medical Sciences, Moscow.
Hybridoma. 1993 Dec;12(6):745-54. doi: 10.1089/hyb.1993.12.745.
Three MAb M2, B6, P1 (IgG1 type) against human urinary trypsin inhibitor (UTI), a glycoprotein with antiinflammatory properties, have been produced by hybridization of mouse myeloma cells P3o1 with spleen cells of immunized mice BALB/c. Competitive ELISA-examination of peroxidase conjugates of M2, B6, and P1 MAb in the presence of the trypsin binding domain shows the highest affinity of M2 antibody for this domain. On the basis of MAb M2 competitive ELISA of UTI concentration in urine is proposed. ELISA detectable changes in the UTI content of urine from patients with nephritis without renal failure can be considered as an early index of renal parenchyma damage.
已经通过将小鼠骨髓瘤细胞P3o1与免疫小鼠BALB/c的脾细胞杂交,制备出三种针对人尿胰蛋白酶抑制剂(UTI,一种具有抗炎特性的糖蛋白)的单克隆抗体M2、B6、P1(IgG1型)。在存在胰蛋白酶结合域的情况下,对M2、B6和P1单克隆抗体的过氧化物酶缀合物进行竞争性酶联免疫吸附测定(ELISA),结果显示M2抗体对该结构域具有最高亲和力。基于单克隆抗体M2,提出了尿液中UTI浓度的竞争性ELISA检测方法。对于无肾衰竭的肾炎患者,酶联免疫吸附测定法可检测到的尿液中UTI含量变化可被视为肾实质损伤的早期指标。